Academic Journal
Navepegritide: First Approval.
| Τίτλος: | Navepegritide: First Approval. |
|---|---|
| Συγγραφείς: | Kang C; Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com. |
| Πηγή: | Drugs [Drugs] 2026 Aug; Vol. 86 (8), pp. 1385-1391. Date of Electronic Publication: 2026 Jun 03. |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 7600076 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1950 (Electronic) Linking ISSN: 00126667 NLM ISO Abbreviation: Drugs Subsets: MEDLINE |
| Imprint Name(s): | Publication: Auckland : Adis, Springer International Original Publication: New York, ADIS Press [etc.] |
| Ιατρικοί όροι (MeSH): | Natriuretic Peptide, C-Type*/therapeutic use , Natriuretic Peptide, C-Type*/administration & dosage , Natriuretic Peptide, C-Type*/pharmacology , Natriuretic Peptide, C-Type*/adverse effects , Natriuretic Peptide, C-Type*/pharmacokinetics , Achondroplasia*/drug therapy , Limb Deformities, Congenital*/drug therapy, Receptor, Fibroblast Growth Factor, Type 3/metabolism ; Receptor, Fibroblast Growth Factor, Type 3/antagonists & inhibitors ; Bone and Bones/abnormalities ; Prodrugs/therapeutic use ; Humans ; Drug Approval ; United States ; Dwarfism ; Lordosis |
| Περίληψη: | Navepegritide (YUVIWEL®) is a prodrug of C-type natriuretic peptide (CNP) developed by Ascendis Pharma for the treatment of achondroplasia and is being investigated for hypochondroplasia. Navepegritide is administered once weekly and designed to provide sustained release and continuous exposure of active CNP, which is needed to counteract the overactive fibroblast growth factor receptor 3 signaling in achondroplasia, resulting in improved growth velocity. Navepegritide recently received accelerated approval in the USA for increasing linear growth in paediatric patients aged ≥ 2 years with achondroplasia with open epiphyses. This article summarizes the milestones in the development of navepegritide leading to this first approval for achondroplasia. (© 2026. Springer Nature Switzerland AG.) |
| Competing Interests: | Declarations. Authorship and Conflict of Interest: During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Connie Kang is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content. Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability: Not applicable. |
| References: | Horm Res Paediatr. 2026 Jan 8;:1-12. (PMID: 41505353) JAMA Pediatr. 2026 Jan 1;180(1):18-25. (PMID: 41247754) J Pharmacol Exp Ther. 2019 Sep;370(3):459-471. (PMID: 31235532) EClinicalMedicine. 2023 Oct 02;65:102258. (PMID: 37823031) Br J Clin Pharmacol. 2022 Nov;88(11):4763-4772. (PMID: 35481707) |
| Substance Nomenclature: | 127869-51-6 (Natriuretic Peptide, C-Type) EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3) 0 (Prodrugs) |
| SCR Disease Name: | Hypochondroplasia |
| Entry Date(s): | Date Created: 20260603 Date Completed: 20260716 Latest Revision: 20260828 |
| Update Code: | 20260828 |
| PubMed Central ID: | PMC13506507 |
| DOI: | 10.1007/s40265-026-02341-x |
| PMID: | 42234372 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!